AB Corporate Bond ETF is a healthcare business based in the US. AB Corporate Bond ETF shares (EYEG) are listed on the NASDAQ and all prices are listed in US Dollars. AB Corporate Bond ETF employs 14 staff and has a trailing 12-month revenue of around $12,059.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $36.78 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $1.86 |
| 200-day moving average | $3.47 |
| Wall St. target price | $11.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.63 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $36.78 from 2024-09-05
| 1 week (2024-08-30) | 0.75% |
|---|---|
| 1 month (2024-08-07) | 2.21% |
| 3 months (2024-06-07) | 4.33% |
| 6 months (2024-03-07) | 3.39% |
| 1 year (2023-09-03) | N/A |
|---|---|
| 2 years (2022-09-03) | N/A |
| 3 years (2021-09-07) | 2,001.71% |
| 5 years (2019-09-06) | 1,168.28% |
| Revenue TTM | $12,059 |
|---|---|
| Gross profit TTM | $-3,553,986 |
| Return on assets TTM | -40.35% |
| Return on equity TTM | -103.8% |
| Profit margin | 0% |
| Book value | $1.47 |
| Market Capitalization | $24.7 million |
TTM: trailing 12 months
We're not expecting AB Corporate Bond ETF to pay a dividend over the next 12 months.
AB Corporate Bond ETF's shares were split on a 1:15 basis on 29 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AB Corporate Bond ETF shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for AB Corporate Bond ETF shares which in turn could have impacted AB Corporate Bond ETF's share price.
Over the last 12 months, AB Corporate Bond ETF's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AB Corporate Bond ETF's is 0.7974. This would suggest that AB Corporate Bond ETF's shares are less volatile than average (for this exchange).
EyeGate Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.